Trinity Capital, an alternative asset manager, committed $30 million in growth capital to Elucent Medical, a medical technology company.
“Elucent is disrupting the field of surgical guidance with its cutting-edge technology,” Lauren Cosentino, managing director, life sciences at Trinity Capital, said. “We are thrilled to be a part of Elucent’s journey as they continue to innovate and improve surgical outcomes.”
“Our EnVisio System gives surgeons confidence before, during and after their surgical procedures so they know they have delivered unparalleled accuracy and precision for their patients. We are in scale mode and are excited to partner with Trinity Capital,” Jason Pesterfield, CEO at Elucent, said. “Trinity Capital’s investment will be key to our continued acceleration of our innovation and commercialization efforts.”
Earlier in 2024, Elucent raised $44 million in its Series C funding round. This additional growth capital will be used to scale operations.
